Oxygenta Pharmaceutical
OXYGENTAPHLTD NSE
Oxygenta Pharmaceutical
HealthcareNSE: OXYGENTAPHLTD BSE: 524636 Pharmaceuticals
Key Fundamentals
MicrocapPharmaceuticalsHealthcareMarket Cap
₹194 Cr
Volatility
Moderate
P/E Ratio
-14.7
EBITDA
₹-15.10 Cr
Return on Equity
41.16%
Debt to Equity
0
Book Value
₹-11.54
EPS
₹0
52W High
₹75
52W Low
₹43
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
2- Company is expected to give good quarter
- Company's median sales growth is 22.1% of last 10 years
Weaknesses
1- Company has low interest coverage ratio.
Growth Rate
Revenue Growth
2.44% lower than
3Y
Net Income Growth
70.87% higher than
3Y
Cash Flow Change
—
ROE
2.49% lower than
3Y
ROCE
-113% lower than
3Y
EBITDA Margin (Avg.)
67.84% higher than
3Y
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 6.86 | 13.08 | 9.15 | 10.55 | 12.62 | 14.01 | 33.21 | 49.47 | 15.13 | 14.3 | 33.93 | 49.61 | 37 |
| Expenses | 10.5 | 15.06 | 11.63 | 12.17 | 14.4 | 16.18 | 37.57 | 51.15 | 21.96 | 18.87 | 38.01 | 49.49 | 36.45 |
| Operating Profit | -3.64 | -1.98 | -2.48 | -1.62 | -1.78 | -2.17 | -4.36 | -1.68 | -6.83 | -4.57 | -4.08 | 0.12 | 0.55 |
| OPM % | -53.06% | -15.14% | -27.1% | -15.36% | -14.1% | -15.49% | -13.13% | -3.4% | -45.14% | -31.96% | -12.02% | 0.24% | 1.49% |
| Other Income | -0.13 | -0.03 | -0.02 | 0.26 | 0.02 | 0.75 | 0.49 | -0.22 | 0.16 | -0.06 | 0 | 0.17 | 0.02 |
| Interest | 0.29 | 0.34 | 0.36 | 0.59 | 0.41 | 0.69 | 0.39 | 2.13 | 0.63 | 0.95 | 1.39 | 1.81 | 2.46 |
| Depreciation | 0.5 | 0.83 | 0.69 | 0.64 | 0.65 | 0.66 | 0.71 | -0.23 | 0.85 | 0.86 | 0.86 | -0.24 | 0.62 |
| PBT | -4.56 | -3.18 | -3.55 | -2.59 | -2.82 | -2.77 | -4.97 | -3.8 | -8.15 | -6.44 | -6.33 | -1.28 | -2.51 |
| Tax % | 0% | -0.63% | 6.48% | -409.27% | -51.42% | 2.89% | -20.72% | -43.42% | -25.03% | -23.45% | -23.38% | 32.81% | -15.94% |
| Net Profit | -4.56 | -3.16 | -3.78 | 8.02 | -1.36 | -2.85 | -3.93 | -2.15 | -6.11 | -4.93 | -4.84 | -1.7 | -2.1 |
| EPS in Rs | -1.36 | -0.94 | -1.13 | 2.4 | -0.38 | -0.8 | -1.06 | -0.58 | -1.65 | -1.33 | -1.31 | -0.46 | -0.57 |
Profit & Loss
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 6 | 12 | 8 | 13 | 21 | 14 | 52 | 61 | 31 | 40 | 109 | 113 | 135 |
| Expenses | 10 | 16 | 13 | 17 | 23 | 22 | 48 | 59 | 38 | 49 | 119 | 128 | 143 |
| Operating Profit | -4 | -4 | -5 | -4 | -2 | -8 | 4 | 1 | -7 | -10 | -10 | -15 | -8 |
| OPM % | -67% | -34% | -59% | -31% | -10% | -57% | 7% | 2.4% | -23% | -24% | -9% | -14% | -6% |
| Other Income | 0 | 0 | 1 | 1 | 0 | 4 | 2 | 1 | -1 | 0 | 1 | 0 | 0 |
| Interest | 0 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 2 | 2 | 5 | 7 |
| Depreciation | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 3 | 4 | 2 | 2 |
| PBT | -7 | -6 | -6 | -4 | -3 | -6 | 3 | 0 | -11 | -14 | -14 | -22 | -17 |
| Tax % | -11% | 0% | 2% | 1% | -7% | -3% | 7% | 24% | 2% | -75% | -28% | -21% | — |
| Net Profit | -6 | -6 | -6 | -5 | -3 | -6 | 3 | -1 | -12 | -3 | -10 | -18 | -14 |
| EPS in Rs | -5.99 | -5.39 | -5.7 | -4.44 | -3.19 | -5.68 | 2.87 | -0.43 | -8.15 | -1.04 | -2.79 | -4.75 | -3.67 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 14 | 14 | 33 | 37 | 37 |
| Reserves | -26 | -32 | -38 | -42 | -45 | -51 | -48 | -49 | -60 | -54 | -63 | -80 |
| Borrowings | 15 | 17 | 19 | 19 | 22 | 27 | 48 | 52 | 68 | 57 | 62 | 110 |
| Other Liabilities | 19 | 24 | 27 | 30 | 34 | 33 | 24 | 14 | 32 | 26 | 46 | 53 |
| Total Liabilities | 18 | 20 | 19 | 17 | 21 | 19 | 34 | 31 | 54 | 63 | 83 | 120 |
| Fixed Assets | 12 | 13 | 12 | 12 | 12 | 11 | 16 | 20 | 28 | 29 | 37 | 48 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 6 | 7 | 6 | 5 | 9 | 7 | 17 | 11 | 26 | 34 | 46 | 72 |
| Total Assets | 18 | 20 | 19 | 17 | 21 | 19 | 34 | 31 | 54 | 63 | 83 | 120 |
Cash Flow
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | -4 | 1 | 1 | 1 | -8 | -3 | -2 | -2 | -2 | -13 | 3 | -28 |
| Investing | 1 | -2 | -1 | 0 | -1 | 0 | -7 | -5 | -10 | -4 | -11 | -14 |
| Financing | 3 | 1 | 0 | -1 | 8 | 3 | 9 | 6 | 11 | 17 | 8 | 43 |
| Net Cash Flow | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free Cash Flow | -7 | -1 | 0 | 1 | -8 | -3 | -8 | -7 | -11 | -17 | -8 | -41 |
| CFO/OP | 104 | -20 | -13 | -33 | 396 | 35 | -37 | -106 | 23 | 135 | -29 | 182 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 38 | 44 | 39 | 14 | 9 | 11 | 11 | 10 | 120 | 68 | 17 | 32 |
| Inventory Days | 84 | 41 | 122 | 57 | 121 | 100 | 121 | 56 | 178 | 149 | 78 | 105 |
| Days Payable | 1,800 | 667 | 599 | 396 | 203 | 190 | 137 | 50 | 362 | 249 | 113 | 174 |
| Cash Conversion Cycle | -1,678 | -582 | -439 | -325 | -73 | -79 | -5 | 16 | -64 | -32 | -18 | -37 |
| Working Capital Days | -616 | -454 | -512 | -438 | -164 | -275 | -14 | 8 | -94 | -89 | -184 | -119 |
| ROCE % | — | — | — | — | — | — | — | -1% | -47% | -42% | -33% | -34% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Oxygenta Pharmaceutical insights
61 extracted metrics + investor summaries across FY11–FY26.
Documents
1
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
27 Apr - Oxygenta says it is not a Large Corporate; initial disclosure not applicable for FY2026-27. 27 Apr - Oxygenta says it is not a Large Corporate; initial disclosure not applicable for FY2026-27.
2
Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
27 Apr - Oxygenta Pharma says it is not a Large Corporate; FY2025-26 debt borrowing nil. 27 Apr - Oxygenta Pharma says it is not a Large Corporate; FY2025-26 debt borrowing nil.
3
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
12h - Oxygenta says it is not a Large Corporate; initial disclosure not applicable for FY2026-27. 12h - Oxygenta says it is not a Large Corporate; initial disclosure not applicable for FY2026-27.
4
Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
12h - Oxygenta Pharma says it is not a Large Corporate; FY2025-26 debt borrowing nil. 12h - Oxygenta Pharma says it is not a Large Corporate; FY2025-26 debt borrowing nil.
5
Compliance As Per Regulation 74(5) Of SEBI (Depositories And Participants) Regulations, 2018 For The Quarter Ended 31St March, 2026
15 Apr - Quarterly Regulation 74(5) compliance filed for securities dematerialized through 31 March 2026. 15 Apr - Quarterly Regulation 74(5) compliance filed for securities dematerialized through 31 March 2026.
Frequently Asked Questions about Oxygenta Pharmaceutical
What does Oxygenta Pharmaceutical Ltd do?
Incorporated in 1990, Oxygenta Pharmaceutical Ltd manufactures Bulk Drugs and API including Pharmaceutical preparation, and Organic Fine Chemicals.
Where is Oxygenta Pharmaceutical Ltd (524636) listed?
Oxygenta Pharmaceutical Ltd trades as OXYGENTAPHLTD on the NSE and under code 524636 on the BSE.
Which sector does Oxygenta Pharmaceutical Ltd belong to?
Oxygenta Pharmaceutical Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Oxygenta Pharmaceutical Ltd?
Oxygenta Pharmaceutical Ltd has a market capitalisation of ₹194.23 Cr, which places it in the Small Cap band.
What is the PE ratio of Oxygenta Pharmaceutical Ltd?
Oxygenta Pharmaceutical Ltd trades at a PE ratio of -14.70, on earnings per share of ₹0, against a book value of ₹-11.54 per share.
What is the 52-week high and low of Oxygenta Pharmaceutical Ltd?
Over the last 52 weeks Oxygenta Pharmaceutical Ltd has traded between ₹43 and ₹75.
What is the Return on Equity (ROE) of Oxygenta Pharmaceutical Ltd?
Oxygenta Pharmaceutical Ltd reported a return on equity of 41.16%. Its debt-to-equity ratio is 0.00.
Company Information
Incorporated in 1990, Oxygenta Pharmaceutical Ltd manufactures Bulk Drugs and API including Pharmaceutical preparation, and Organic Fine Chemicals.
Website oxygentapharma.com
CEO Mr. Prasad Reddy Battinapatla
Employees 175
Listed 1997-10-20
Face Value ₹ 10
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/524636.md for Oxygenta Pharmaceutical Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.